Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Docetaxel, and Bevacizumab in Sarcoma
NCT00887809Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2009
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in leiomyosarcoma (LMS), Malignant Fibrous Histiocytoma (MFH), pleomorphic liposarcoma (PLS), rhabdomyosarcoma (RMS), angiosarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
leiomyosarcoma (LMS)Malignant Fibrous Histiocytoma (MFH)pleomorphic liposarcoma (PLS)rhabdomyosarcoma (RMS)angiosarcoma
Beyond the preview
Go deeper on NCT00887809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887809.